Cue Biopharma to Detail Treg Modulation Strategy at R&D Day

Event summary

  • Cue Biopharma will host a virtual R&D Day on April 7, 2026, at 10:00 AM EDT.
  • The event will feature KOLs Richard DiPaolo, PhD, and Jonathan Kay, MD, discussing CUE-401.
  • CUE-401 is the company’s lead asset targeting autoimmune and inflammatory diseases.
  • DiPaolo’s research focuses on regulatory T cells (Tregs) and their role in autoimmunity.
  • Kay has extensive experience in clinical trials for therapies targeting rheumatic diseases.

The big picture

Cue Biopharma’s Immuno-STAT platform represents a novel approach to autoimmune disease treatment, aiming to induce tolerance rather than broad immunosuppression. The R&D Day provides a crucial window into the validation of this strategy and the progress of CUE-401, which faces the challenge of demonstrating efficacy and safety in a competitive market with significant unmet need. The involvement of established KOLs suggests a degree of external validation, but the data presented will be the ultimate arbiter of the asset’s potential.

What we're watching

Clinical Data
The success of CUE-401 hinges on demonstrating meaningful clinical efficacy and safety profiles, and the R&D Day will be a key opportunity to assess early data trends.
Regulatory Pathway
Given the complexity of modulating T cell function, the FDA’s acceptance of CUE-401’s mechanism of action and clinical trial design will be a critical determinant of its commercial viability.
Competitive Landscape
The autoimmune and inflammatory disease space is crowded; the R&D Day will reveal how Cue Biopharma differentiates CUE-401 from existing and emerging therapies.